Kornimate/medical-research-clean huggingface dataset:
development of 3d multi-parametric ultrasound (mpus) as a decision support tool for patients

Conditions: Liver Cancer, Adult

Summary: this clinical trial studies how well 3-dimensional multi-parametric ultrasound (3d mpus) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3d-mpus is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.


Eligibility criteria:
inclusion criteria: 1. participant is planned to undergo a new course of cancer therapy\*. 2. participant is age \>/=18 years. 3. participant has at least one target lesion (≥1cm and \<14cm) amenable to imaging with ultrasound 4. participant is willing to comply with protocol requirements. 5. participant has given written informed consent to participate in this study. * any line of cancer therapy is allowed, including systemic and localized treatments, after any prior treatment. for systemic combination treatments, prior treatment with either drug is allowed at the discretion of the investigators, including rechallenges with the same drug combination, for example upon progression on imaging after a treatment break. for combination treatments where patients start treatment with different drugs at different times, the start date of treatment is determined at the discretion of the investigators and can be the start date of the first drug or of the combination treatment. repeat participation in the study is allowed, if patients are eligible again per their treatment plan exclusion criteria: 1. participant has documented anaphylactic or other severe reaction to any ultrasound contrast media or polyethylene glycol (peg). 2. participant has any comorbid condition\*\* that, in the opinion of the treating provider or the protocol director, compromises the participant's ability to participate in the study. * examples: any mental condition that compromises the ability to follow a consent discussion, or to make informed decisions (except if represented by a legally authorized representative \[lar\]); any condition that makes the participant not a good candidate to have ultrasound exams with contrast agent.

Keywords: diagnostic study
comparison of three lancing devices regarding capillary blood volume and lancing pain intensity.

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: a randomized single-blind study with the use of three lancing devices equipped with personal lancets. every device will be studied for three lancet sizes: 28g, 30g, and 33g with the minimum and maximum puncture depth setting.


Eligibility criteria:
inclusion criteria: * patients with diagnosed diabetes type 1 or 2 , * aged 18 - 50, * period of suffering from diabetes \>2 years, * performing on average 3-8 daily measurements of glycaemia, * glycaemia at the moment of the beginning of the study between 70 and 200 mg/dl. exclusion criteria: * glycaemia below 70 mg/dl or glycaemia above 200 mg/dl at the moment of the beginning of the study, * previously diagnosed hemorrhagic diathesis or heavy bleedings in the past (also those without a medical diagnosis), * anticoagulant (thrombolytic medication) therapy within 3 weeks prior to the study or on the day of the study, * non steroidal anti-inflammatory drugs (nsaid) treatment 1 week prior to the study or on the day of the study, * patients with signs of dehydration, * patients who are currently participating in another clinical study, * currently diagnosed or reported by the patient skin diseases, nervous system diseases, psychiatric diseases, etc., which, in the opinion of the person conducting the study, disqualify the patient from the participation in the study, in care for the patient's well-being.

Keywords: lancing device lancet
causes of traffic collisions of ambulance cars at the prague emergency medical services

Conditions: Traffic Collision; Transport Accident

Summary: the aim of the project is to increase the protection of patients, employees and the organization by means of data collection about traffic collisions of ambulance cars.

published research studies have shown not only that approximately half of emergency medical services (ems) providers show signs of severe fatigue before traffic collision, but also that drowsy or tired ems providers are significantly more often injured at work. among the circumstances and factors contributing to the collisions, including environmental, road or equipment factors, the real causes of the collisions remain unclear, but might be investigated through interviews with participating drivers. the aim is to increase the protection of patients, employees and the organization by collect data in both qualitative and quantitative ways and to identify factors and measurable variables that might lead to strengthen healthy driving habits under the blue lights. the factors associated with ambulance accidents are not similar to those of the general driving population. the in-depth analysis of the whole problem aims not only to clarify the causes of collisions, but especially to create prevention steps so that such situations occur as little as possible. the methodology will use the so-called mixed design - a combination of in-depth interviews with participating members of collisions (employees, or patient / relative), data from the road-scans and qualitative data including measurable variables. a video-analysis of the collision will be performed. all data will be recorded anonymously - each participant in the accident will receive a special number for coding, under which they will appear. data will be presented both in descriptive statistics and after statistical analysis (chi square test for independence and fischer's exact test at the level of significance = 0.05). in terms of qualitative data, in-depth interviews and their coding will be performed using grounded theory (based on strauss and corbin methodology). the aim is to gain the same view of events and their actions as the members of the group. the sample of participants depends on collision rate, which was 50 incidents in the year 2020 (expecting approx. 100 cases in 2 years).

Eligibility criteria:
inclusion criteria: * ambulance driver involved in a traffic collision of ambulance car * consent to participate in the study * video recording of the collision exists and can be used exclusion criteria: * disagreement with participating in the study * video recording of the collision cannot be obtained

Keywords: traffic collision safety ambulances emergency medical services
conservative therapy of proximal phalanx fractures - comparing the lucerne cast with finger splinting

Conditions: Proximal Phalanx Fracture

Summary: the purpose of this prospective randomized controlled clinical trial is to evaluate if the lucerne cast leads to a better functional outcome than a forearm cast with a finger splint in patients with a proximal phalanx fracture.

this study represents a prospective randomized controlled clinical trial comparing two different conservative treatment options in patients with proximal phalanx fractures. patients meeting the inclusion criteria will be enrolled in the present study provided they give their consent. informed written consent will be obtained. randomization will be performed according to the consort guidelines of prospective randomized trials using the software "randomizer" by the medical university of graz. patients allocated to the control group will receive a forearm cast with a finger splint, while patients in the study group will receive the lucerne cast. both groups will receive the allocated cast for 4 weeks. clinical outcome will be assessed 12 weeks after trauma.

Eligibility criteria:
inclusion criteria: * proximal phalanx fracture in the fingers (ii - v) * patient age between 18 and 70 years exclusion criteria: * condylar fracture * avulsions of the collateral ligament * pathologic fracture * intraarticular fracture * patients unable to consent * polytraumatized patients * patients initially presenting more than 7 days after injury * pregnancy * compound fractures * multiple hand injuries
context - remote ischemic conditioning in renal transplantation - effect on immediate and extended kidney graft function

Conditions: Kidney Transplantation; Delayed Graft Function; Acute Kidney Injury; Glomerular Filtration Rate

Summary: the purpose of this study is to determine whether remote ischemic conditioning can improve the outcome after renal transplantation with deceased donor. remote ischemic conditioning is performed on the patient receiving a kidney from a deceased donor. remote ischemic conditioning is done during the operation by inflating a tourniquet on the patients leg before opening the blood circulation to the kidney. the study focus on both the immediate kidney function after the transplantation, but also on the extended kidney function one year after the transplantation.


Eligibility criteria:
inclusion criteria: * age 18 and above * received information, signed consent * candidate for kidney transplantation from deceased donor exclusion criteria: * can't give informed consent * av-fistula in the leg opposite the site where the graft will be placed * threatening ischemia in the leg * if donor is a small child * if the patient receives a double transplant

Keywords: renal transplantation glomerular filtration rate remote ischemic preconditioning remote ischemic conditioning
community-based telemedicine to reduce risk to georgia veterans with post traumatic stress disorder

Conditions: Post Traumatic Stress Disorder, PTSD

Summary: the investigator proposes to examine treatment for posttraumatic stress disorder for veterans who served in iraq and afghanistan provided through telemedicine which connects patients to doctors in different locations using the internet. in this study, veterans will receive prolonged exposure therapy (pe). this treatment has been shown to be effective in reducing ptsd symptoms. for this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. the first 2 sessions of each treatment will involve education, rational and treatment preparation. sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. the purpose of this study is to determine if this treatment is effective when given through telehealth. to this end, the investigators propose to enroll up to 20 individuals who will access the investigators services through the ga telehealth network who has hundreds of telehealth sites across the state of georgia. patients will go to these sites to access the investigators therapists using ga telehealth equipment. the investigators hypothesize that pe delivered remotely through telemedicine will work to reduce the symptoms of ptsd.


Eligibility criteria:
inclusion criteria: * participants must meet dsm-iv criteria for ptsd due to exposure to a trauma while serving in operation iraqi freedom, operation enduring freedom-afghanistan, and/or operation new dawn. * patients must be literate in english. * patients must be medically healthy or medically stable such that the stress of the therapy is not contraindicated. * participants must comprehend his or her role in treatment and the risks involved in order to be entered. exclusion criteria: * patients with a history of mania, schizophrenia, or other psychoses * patients with prominent suicidal ideation * patients with current alcohol or drug dependence * patients with special medical conditions such as pregnancy, renal insufficiency, those with various chronic diseases or a history of significant head injury

Keywords: ptsd trauma combat trauma veterans telemedicine prolonged exposure
aggrenox prevention of access stenosis

Conditions: Kidney Failure

Summary: the objective of the study is to determine whether aggrenox (boehringer-ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. this record previously included information for both the graft and fistula trials.


Eligibility criteria:
inclusion criteria: * age 18-21 depending on state regulations * life expectancy of at least six months * chronic renal failure with anticipated start of hemodialysis within six months of enrollment, or current dialysis dependence * a new or planned arteriovenous (av) graft placed in any location for the purpose of hemodialysis. (any type of graft material and any configuration of the access is acceptable). * the patient is expected to stay at a participating dialysis facility for at least 6 months. * the patient's physician(s) will allow the patient to participate. * ability to give informed consent. exclusion criteria: * women must not be pregnant, breastfeeding, or plan to be pregnant during the course of the study. * the presence of ongoing bleeding. * the presence of a known bleeding disorder (e.g., hemophilia or von willebrand's disease). * recent bleeding episode requiring transfusion within 12 weeks of entry. * the presence of acute ulcer disease. acute ulcer disease is defined as a new diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the initiation of treatment with proton pump inhibitors, h2 blockers or therapy for helicobacter pylori within three months prior to obtaining consent. * known allergy or adverse reaction to aggrenox or any of its study components (dipyridamole and aspirin). * required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other antiplatelet agents other than aspirin. * current uncontrolled hypertension with systolic blood pressure in excess of 200 mm hg or diastolic blood pressure in excess of 115 mm hg. * baseline platelet count less than 75,000/mm3. * known advanced liver disease with decompensated cirrhosis, jaundice, ascites or bleeding varices. * current problem with substance abuse. * concurrent participation in another medical intervention trial. * anticipated non-compliance with medical care based on physician judgment. * patient refusal.

Keywords: graft failure access blood flow monitoring clinical trial vascular access fistula failure hemodialysis vascular access
effects of h. pylori eradication on the gastric preneoplastic lesion and neoplasm after esd

Conditions: Helicobacter Pylori Infection; Early Gastric Cancer; Endoscopic Resection

Summary: this study evaluates whether helicobacter pylori eradication improves precancerous lesions including glandular atrophy and intestinal metaplasia as well as metachronous cancers or dysplasias after endoscopic mucosal resection for gastric cancer.

helicobacter pylori is a primary etiological agent leading to chronic gastritis and peptic ulcer. the organism is also associated with gastric cancer in epidemiological studies. however detailed mechanism of carcinogenesis remains unknown. histolopathological studies indicate that chronic h. pylori infection progresses over decades through stages of chronic gastritis, atrophy, intestinal metaplasia, dysplasia and cancer. gastric atrophy and intestinal metaplasia are considered as precancerous lesions, but whether h. pylori eradication improves these lesions and prevents metachronous gastric cancer is controversial. and the issue has not been evaluated in gastric cancer patients. however, despite the conflicting evidences from two open labelled randomized controlled trials, current guidelines from various regions recommend h. pylori eradication treatment in patients who were treated for gastric cancer by surgically or endoscopically. thus, it is important to evaluate whether h. pylori eradication can improve known precancerous lesion, i.e. glandular atrophy and intestinal metaplasia in gastric cancer patients. such histological improvement can eventually reduce secondary gastric cancer development and provide evidence for current guidelines.

Eligibility criteria:
inclusion criteria: * early gastric cancer or high grade dysplasia confirmed by endoscopy * histologically confirmed well or moderately differentiated adenocarcinoma, or high grade dysplasia * submucosal invasion is not suspected * no evidence of ulceration or ulcer scar within the lesion * helicobacter pylori infection was confirmed by histological evaluation and rapid urease test * pre op ct stage: ia (t1n0m0) according to uicc tnm classification system * informed consent should be signed exclusion criteria: * recurrent gastric cancer * previous serious side effect to antibiotics * h. pylori eradication treatment history * poorly differentiated adenocarcinoma or signet ring cell carcinoma * undergoing operation due to complication of emr * undergoing operation due to remnant cancer * other malignancy within the past 5 years * pregnant or nursing women * serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal failure, cardiovascular diseases * psychiatric disorder that would preclude compliance

Keywords: h. pylori eradication atrophy intestinal metaplasia endoscopic resection stomach neoplasm
the use of novel diagnostic tools to increase detection of early fibrosis in cystic fibrosis related liver disease to improve clinical management

Conditions: Cystic Fibrosis; Liver Fibroses; Cystic Fibrosis Liver Disease

Summary: cystic fibrosis (cf) is a genetic condition which affects 1 in 2500 newborn infants and is the commonest genetic condition in the uk. 1 in 25 of the white population carry the mutation. the genetic defect prevents the movement of fluids from cells, leading to thickened secretions and injury. with improvements in treatments from the commonest organ affected, the lungs, patients born with cf now can expect to live into their 40s with more than 60% living past 16. though better, more can be done. as treatments from lung complications have improved, the management of liver disease (second commonest organ involved) remains unchanged for a considerable time. treatment options are limited with liver transplant the only curative option. though potentially life-saving, it has risks and an organ shortage means alternative treatment options are desperately needed. identifying those with or at risk of cystic fibrosis related liver disease is difficult due to inadequate diagnostic tools. routine blood tests are unreliable; therefore specific blood tests to identify scarring of the liver (biomarkers) are urgently needed. ultrasound scan, the recommended diagnostic investigation, is only accurate in identifying the late stages of liver disease. for new therapies to be most effective we need to be able to identify patients at a much earlier stage. this study will use multi-modality testing, including imaging techniques such as fibroscan, mri scan and blood tests (biomarkers), to diagnose those with liver scarring and use this to better categorise disease.


Eligibility criteria:
inclusion criteria: 1. male or female \> 18 years of age 2. females will be non-pregnant and non-lactating\* (for mri scan only) 3. 20 patients with confirmed diagnosis of cf, 20 with cfld and 20 healthy volunteers * women of childbearing potential (i.e. not surgically sterilised or \<1 year post menopause) will be required to: 1. confirm they are not currently breastfeeding 2. undergo a serum pregnancy test (serum β-hcg) exclusion criteria: 1. contraindication to magnetic resonance imaging scanning (including claustrophobia) or gadolinium-based contrast agent 2. egfr \< 50 ml/min/1.73m2 3. pregnant or breast-feeding women. 4. any other condition, which in the opinion of the research team may put participants at risk during the study.
study evaluating mac-321 in non-small cell lung cancer refractory to platinum-based therapy

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms

Summary: this non-randomized, open-label clinical trial is designed to determine safety and clinical activity of a new chemotherapeutic agent, mac-321, when given intravenously to patients with non-small cell lung cancer. clinical activity will be evaluated by determining the percentage of patients with an objective tumor response after treatment with mac-321. patients must have been previously treated with a platinum-containing chemotherapy regimen. a total of 96 patients will be enrolled in this trial. eligible patients will receive mac-321 intravenously every 3 weeks for up to a total of 6 courses of treatment. all patients will receive mac-321 at the same dose. mac-321 is an experimental drug, and is not offered outside of this research trial.


Eligibility criteria:
inclusion criteria: * recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen containing a platinum agent * recovery from all acute side effects of prior therapies (with the exception of hair loss) * adequate bone marrow, liver, and kidney function exclusion criteria: * more than 2 prior chemotherapy regimens for treatment of advanced or metastatic non-small cell lung cancer. (treatment given in conjunction with surgery will not be included in the maximum of 2 prior regimens) * radiation therapy, chemotherapy or any other anticancer therapy within 28 days of beginning study * symptomatic brain metastases

Keywords: non-small-cell lung carcinoma lung cancer cancer of lung
head and neck phase iii iressa versus methotrexate refractory: iressa versus methotrexate (imex)

Conditions: Squamous Cell Carcinoma of the Head and Neck

Summary: this study is to compare zd1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.


Eligibility criteria:
inclusion criteria: * histological confirmation of evidence of squamous cell carcinoma of the head and neck. * tumors have progressed after primary treatment with radiation or chemoradiation and have failed to respond to at least one course of standard platinum-based chemotherapy. * tumors have progressed after primary treatment with radiation or chemoradiation and are considered unsuitable for platinum-based chemotherapy. exclusion criteria: * carcinomas of the post-nasal space, thyroid, sinus or salivary gland tumors. * isolated recurrent disease that may be amenable to local therapy; e.g., surgical intervention or radiation therapy. * known severe hypersensitivity to zd1839, methotrexate or any of the excipients of these products.

Keywords: squamous cell carcinoma of the head and neck
the influence of hdl function on cognitive function

Conditions: Older People With Diabetes Mellitus

Summary: older people with diabetes mellitus are at risk of cognitive decline and dementia. we therefore propose to examine the potential influence of hdl function on global cognitive function and brain structures in older people with dm.


Eligibility criteria:
inclusion criteria: participants with dm exclusion criteria: participants refuse blood taking